Carisma Therapeutics Q3 2025 Earnings Results & Report

Carisma Therapeutics EPS Results

• Actual EPS: $1.07
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A
• EPS Beat Rate: 5 of last 8 quarters

Carisma Therapeutics Revenue Results

• Actual Revenue: $45.25 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Carisma Therapeutics (NASDAQ:CARM), Inc. is a clinical-stage biotechnology company focused on developing engineered macrophage and monocyte therapies for cancer and other serious diseases. Its approach is designed to harness the natural ability of these immune cells to locate and interact with disease sites while enhancing their ability to recognize and attack abnormal cells.

The company’s technology platform uses genetic engineering to create targeted cell therapies, including chimeric antigen receptor macrophage (CAR-M) candidates. Carisma’s programs are intended to address tumors that may be difficult for conventional immune-cell therapies to reach or treat, including solid tumors. Its lead programs have focused on HER2-targeted therapies, such as CT-0525, an investigational CAR-monocyte therapy being evaluated in clinical development.

Carisma Therapeutics was founded through research associated with the University of Pennsylvania and has established operations in Philadelphia. The company became publicly traded on the Nasdaq under the symbol CARM in 2023. Its leadership has included Steven Kelly as chief executive officer. Carisma’s research and development activities are primarily focused on advancing its macrophage-based immunotherapy platform and clinical pipeline.